Health Tech Forward Event 2024

Vorwerk Ventures is an independent € 150m Venture Capital Fund with € 400m under management. We invest in founders with sustainable business models that have a positive impact. We define ourselves through a strong commitment towards consumer-facing digital businesses, but we also go beyond and invest in selected B2B companies that match our sector expertise. Our unique experience in addition to an outstanding track record provides added value for forward-thinking tech entrepreneurs. Headquartered in Berlin Germany, we are constantly on the look-out for promising opportunities starting with Seed/Series A investments of € 1m to € 10m and ensuring continuous support by reserving up to € 15m for upcoming financing rounds. An outstanding founding team, a unique product or service addressing a substantial market framed by a strong business model are key requirements to us when it comes to making an investment decision.

Operator of a global investment firm focused on the healthcare industry. The company's capital funding services are offered in fields such as diagnostics, pharmaceutical research, home care, orthopedics, animal health, occupational health, care delivery services, cardiovascular devices and food safety, providing projects in the healthcare sector with proactive support to achieve their goals.

Universit_tsklinikum Essen is a medical university and has developed an app iNephro Medikamentenplan for iPhone and iPad users.

Developer of a caregiving assistance application designed to organize the challenges of home care effectively. The company's platform offers an intelligent assistant to provide individualized answers to questions, detailed guides, the option to chat with experts, step-by-step guidance, care plans, and checklists, enabling caregivers with the tools, information, and support they need to fulfill their responsibilities.

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Provider of sexual health services headquartered in London, England. The company offers services such as access to STI testing, chlamydia treatment, partner notification, and contraception and clinicians are available to advise and support by text message, phone or email.

Operator of an anti-contract research organization intended to deliver end-to-end clinical trials for health and biotech companies. The company's software allows access to electronic health records, design, patient recruitment, clinical data capture, monitoring, and project management, while reducing the risk of clinical trial failure, enabling health experts to accelerate clinician trials and improve patient treatment outcomes.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Tandem Health SC is a Sumter, SC based private company whose line of business is Medical doctor's office

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.